News

Published on 18 Jun 2024 on Insider Monkey · via Yahoo Finance

Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy...


Article preview image

We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) stands against the other biotech penny stocks.

Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities

In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities. Particularly biotech is anticipated to profit, despite the dangers of continuous mergers and acquisitions. Traders ought to exercise caution. With an 11.8% CAGR, the worldwide biotechnology market is expected to reach USD 4.25 trillion by 2033. It is expanding quickly. The U.S. market is projected to increase at an 11.90% CAGR to reach USD 763.82 billion by 2033 from its 2023 valuation of USD 246.18 billion. In 2023, the U.S. led North America in terms of revenue share.

NASDAQ.BDTX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor...

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type...

Benzinga · via Yahoo Finance 22 Sep 2024

Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy...

We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we a...

Insider Monkey · via Yahoo Finance 18 Jun 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of...

Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock...

Simply Wall St. via Yahoo Finance 22 May 2024

Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?

Investors are always looking for stocks that are poised to beat at earnings season and Black Diam...

Zacks via Yahoo Finance 10 May 2024

With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional...

Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock...

Simply Wall St. via Yahoo Finance 5 Dec 2023

Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update

<img src=https://s.yimg.com/ny/api/res/1.2/DdMmfHVZsMIU_n.1Gz3UTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2M...

GuruFocus.com via Yahoo Finance 6 Nov 2023

Black Diamond Therapeutics Insider Ups Holding By 82% During Year

From what we can see, insiders were net buyers in Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX...

Simply Wall St. via Yahoo Finance 25 Oct 2023

Co-founder of cancer biotech Black Diamond replaced as CEO

The co-founder of a Cambridge biotech has been replaced as CEO. Black Diamond Therapeutics Inc....

American City Business Journals 18 Sep 2023

10 Healthcare Stocks with Insider Buying

In this article, we will take a look at the 10 healthcare stocks with insider buying. To see more...

Insider Monkey via Yahoo Finance 17 Aug 2023

Institutions profited after Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) market cap rose US$152m...

Key Insights Significant control over Black Diamond Therapeutics by private equity firms implies ...

Simply Wall St. via Yahoo Finance 28 Jun 2023